A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participan… (NCT06993480) | Clinical Trial Compass
Active — Not RecruitingPhase 2
A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
China20 participantsStarted 2025-07-15
Plain-language summary
AB-10-8005 is a single-center, open-label Phase II clinical study to evaluate the antiviral activity and immune responses of AHB-137 injection in participants with CHB treated with nucleos (t) ide analogues.
Who can participate
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Voluntarily participated in the study and signed an informed consent form;
* Aged between 18 and 55 years at the time of signing the informed consent form;
* Body mass index (BMI) within the range of 18-30 kg/ m2;
* HBeAg negative or positive at screening;
* HBsAg or HBV DNA positive for at least 6 months;
* Have been on continuous nucleos(t)ide analogues antiviral therapy for more than 6 months prior to screening;
* 100 IU/mL \< HBsAg ≤ 3000 IU/mL and HBV DNA \< 100 IU/mL at screening;
* Alanine aminotransferase (ALT) ≤ 2 × upper limit of normal (ULN);
* Effective contraception as required.
Exclusion Criteria:
* Clinically significant abnormalities other than a history of CHB infection;
* Concomitant clinically significant other liver diseases;
* Any serious infection other than CHB infection requiring intravenous anti-infective therapy within 1 month prior to screening;
* Active hepatitis C, Human immunodeficiency virus (HIV) positive, syphilis positive;
* Liver stiffness value (LSM) \> 9.0 kPa at screening;
* Diagnosis or suspicion of hepatocellular carcinoma, or alpha-fetoprotein (AFP) concentration ≥ 20 ng/mL at screening;
* Participants with confirmed or suspected hepatic decompensated hepatitis B cirrhosis;
* Liver biopsy at screening assessed severity of activity ≥ G3 grade and/or fibrosis reaching S4 stage;
* History of extrahepatic disease possibly related to HBV immune status;
* Ongoing or taking any immunosuppressive medication within 3 mo…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Proportion of participants with serum HBsAg < limit of detection (LOD) 0.05 international unit per milliliter (IU/mL) and Hepatitis B Virus (HBV) DNA < lower limit of quantification (LLOQ) with or without HBsAb seroconversion.